Is this you? Create Your Porfile
Avatar

H. Johnson

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where H. Johnson is active.

Explore More

Publication

Featured researches published by H. Johnson.

Journal of Crohns & Colitis | 2017

P379 Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?

H. Johnson; K. Wade; C. Hovell; S. Weaver; S. McLaughlin

Background: We and others have previously reported the utility of low dose azathioprine and allopurinol co-therapy in patients who develop side effects to standard dose azathioprine. This practice allows patients the convenience of continuing an oral drug and leads to health care savings by avoiding

Journal of Crohns & Colitis | 2014

P549 Azathioprine in the elderly – Is it tolerated and is it safe?

S. Dharmasiri; H. Johnson; S. McLaughlin; S. Weaver

Journal of Crohns & Colitis | 2014

P419 Low dose azathioprine and allopurinol in azathioprine intolerant patients: is it tolerated and is it effective in IBD?

H. Johnson; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2018

P523 New guidance on therapeutic drug monitoring; potential clinical and cost implication

R Felwick; H. Johnson; H. Dewhurst; E Cadogan; C. Hovell; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2017

P645 The introduction of infliximab therapeutic drug level monitoring for is associated with cost savings in a cohort of patients in a large district general hospital

S. Whiteoak; H. Johnson; C. Hovell; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2017

P649 Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects

K. Wade; H. Johnson; K. Slinger; C. Hovell; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2014

P420 Low dose azathioprine and allopurinol co-therapy: is it safe to use without metabolite monitoring?

B. Eross; H. Johnson; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2013

P339 The routine measurement of thiopurine metabolite levels results in dose optimisation in one third of IBD patients; results from a district general hospital

H. Dewhurst; H. Johnson; J. Begley; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2013

P444 Low-dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital

H. Johnson; H. Dewhurst; S. Weaver; S. McLaughlin

Journal of Crohns & Colitis | 2013

P446 Long term outcome of azathioprine therapy in 353 consecutive IBD patients

H. Johnson; K. Smith; N. Jarrett; S. McLaughlin; S. Weaver

Explore More

Collaboration

Dive into the H. Johnson's collaboration.

Top Co-Authors
Avatar

S. McLaughlin

Royal Bournemouth Hospital

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge